BIOTRONIK Introduces World’s First and Only System CE Approved for Left Bundle Branch Area Pacing (LBBAP) BIOTRONIK Launches Its Complete Conduction System Pacing (CSP) Solution Consisting of the World’s First Approved CSP System Alongside Comprehensive Training and Expert Support
Following the recent CE approval of the Solia S lead1 for LBBAP, BIOTRONIK proudly announces the world’s first and only complete CSP system, now fully CE-approved for Left Bundle Branch Area Pacing (LBBAP).2
The BIOTRONIK CSP system comprises three proven components: Selectra 3D catheters offering exceptional handling3, Solia S leads – the most popular choice of stylet-driven leads for LBBAP4 providing enhanced stability3, and the Amvia pacemaker family, the first and only family approved for LBBAP.2 Notably, this groundbreaking system is the world’s first and only approved MR Conditional CSP system for LBBAP.2
Dr. Francesco Zanon of Santa Maria della Misericordia Hospital in Rovigo, Italy, who earlier this month implanted the world’s first fully approved CSP system in a male patient suffering from sinus node disease (SND) and paroxysmal atrio-ventricular block (AVB), with moderately reduced ejection fraction (EF), said: “I am really satisfied with the usability and performance of BIOTRONIK's CSP system. I am empowered to deliver superior clinical treatments to my patients using a practical and easy-to-use system that is completely dedicated to LBBAP.”
LBBAP, utilizing the heart's natural conduction system efficiency, is recognized as the preferred approach to physiologic pacing.5 BIOTRONIK’s commitment to CSP has enabled the company to develop a dedicated CSP portfolio. Providing comprehensive training and expert technical support, BIOTRONIK is dedicated to fostering confidence among experienced physicians as well as those new to CSP.
“By introducing the world’s first approved and complete CSP system, we are revolutionizing cardiac rhythm care while leading the CSP field. BIOTRONIK is listening to clinicians' needs, ensuring continuous advancement for the benefit of our patients and healthcare providers," stated Dr. Alexander Uhl, CEO at BIOTRONIK.
BIOTRONIK’s CSP Solution will be showcased at the EHRA Congress in Berlin from April 7-9, 2024. Visitors can attend the CSP-dedicated lunch symposium focused on mastering the stylet-driven approach for LBBAP, as well as the BIOTRONIK booth expert talks led by experienced CSP implanters to gain practical insights and best practice tips & tricks for LBBAP.
For more information about BIOTRONIK’s complete Conduction System Pacing (CSP) Solution, visit the BIOTRONIK booth (D300) at the EHRA Congress.
-END-
Disclaimer: Selectra 3D and Solia S are not currently approved for CSP indications in the United States. Content is not intended for United States healthcare providers. Local regulatory approval may vary by country.
References:
- The intended purpose of Solia S 53 and Solia S 60 now explicitly covers Left Bundle Branch Area Pacing (LBBAP).
- BIOTRONIK Amvia technical manual; Medtronic Azure XT DR MRI SureScan™ manual; Boston Scientific Accolade MRI™ technical manual; Abbott Assurity MRI™ user’s manual; MicroPort Alizea™ implant manual.
- De Pooter J, Bulava A, Gras D, et al. Utility of a guiding catheter for conduction system pacing. An early multicenter experience. Heart Rhythm O2. 2023; 288(24): 3115.
- Jastrzębski M, Kiełbasa G, Cano O, et al. Left bundle branch area pacing outcomes: the multicentre European MELOS study. Eur Heart J. 2022; 43(40): 4161-4173.
- Keene D, Anselme F, Burri H, et al. Conduction system pacing, a European survey: insights from clinical practice. Europace. 2023; 25(5): 1-9.
Download Our CSP Media Kit:
About BIOTRONIK:
At BIOTRONIK, patient well-being is our top priority and has been for 60 years. BIOTRONIK is a leading global medical technology company with products and services that save and improve the lives of millions suffering from heart and blood vessel diseases as well as chronic pain. Driven by a purpose to perfectly match technology with the human body, we are dedicated innovators who develop trusted cardiovascular, endovascular and neuromodulation solutions. BIOTRONIK is headquartered in Berlin, Germany, and is represented in over 100 countries.
Related Press Releases
-
Image
BERLIN, GermanyPress ReleaseB3 Clinical Study Results Reveal that Closed Loop Stimulation (CLS) Rate-Adaptive Pacing Delays Subclinical AF in Sinus Node Disease (SND) patients
During a Late-Breaking Session at the annual meeting of the European Heart Rhythm Association (EHRA), Dr. Ennio C. L. Pisanò, Vito Fazzi Hospital, Lecce, Italy, unveiled groundbreaking clinical findings from the randomized, multicenter B3 study 1 regarding the impact of CLS on the incidence of Subclinical AF in SND patients. CLS is a unique rate-adaptive algorithm that is able to detect not only movement but emotional stress, physical stress, or physical activity. In essence, CLS is an impedance-based sensor that translates changes in cardiac contractility to increase heart rate –mimicking a
-
Image
BERLIN, GermanyPress ReleaseBIOTRONIK Introduces New BIOMONITOR IV Insertable Cardiac Monitor with Artificial Intelligence at EHRA Congress 2024
BIOTRONIK announced the CE approval and first European implant of its latest insertable cardiac monitor (ICM). The BIOMONITOR IV features artificial intelligence (AI) for false positive reduction. It is the only ICM on the market with premature ventricular and atrial contraction (PVC and PAC) discrimination capabilities, 1,2 as well as industry-leading signal quality and transmission success for highly reliable remote patient management. 3 False positive detections may take clinicians a considerable amount of time to review. That’s why BIOMONITOR IV features SmartECG, an intelligent system
-
Image
BERLIN, GermanyPress ReleaseNew BIOlMASTER.Selectra 3D Study Highlights Exceptional Safety and Performance of BIOTRONIK’s Selectra 3D Guiding Catheter for CSP
In a recent prospective, international, multicenter, nonrandomized trial, the BIO|MASTER.Selectra 3D study assessed the performance and safety of BIOTRONIK’s Selectra 3D guiding catheter, revealing compelling insights into its ease of handling and effectiveness. Conducted across 10 centers in Australia, Hong Kong and Europe, the study included 157 patients who underwent a CSP procedure for bradycardia pacing or heart failure indications. The results of this research have been published in the Heart Rhythm O 2 journal. 1 Key Findings of the BIO|MASTER.Selectra 3D Study: High Success Rate in
-
Image
BERLIN, GermanyPress ReleaseBIOTRONIK’s DX Technology Reaches Significant Milestone: 100,000 DX Devices Implanted
BIOTRONIK announced the milestone achievement of 100,000 implanted single-chamber implantable cardioverter-defibrillators (ICDs) equipped with DX Technology. Since the introduction of this unique technology in 2009, clinicians in more than 80 countries across all continents use DX ICDs. “Reaching this significant milestone, BIOTRONIK stands as a proud pioneer and partner in cardiac rhythm management. Our commitment to quality and focus on innovation sets us apart, allowing us to introduce meaningful innovations in the market, such as DX Technology, that make a real difference in patients’